| Literature DB >> 27721716 |
Cornelia Liedtke1, Hans-Christian Kolberg2.
Abstract
Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g., antibody-based approaches). These agents may be employed alone or in combination based on the patient's breast cancer subtype. Therefore, characterization of the disease phenotype is necessary and may include biopsy of the metastatic site. Novel therapeutic approaches include immunologic therapies, PARP inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, which are currently under investigation in clinical trials.Entities:
Keywords: Chemotherapy; Clinical trials; Endocrine therapy; Metastatic breast cancer; Molecular breast cancer subgroups; Targeted therapy
Year: 2016 PMID: 27721716 PMCID: PMC5040928 DOI: 10.1159/000447549
Source DB: PubMed Journal: Breast Care (Basel) ISSN: 1661-3791 Impact factor: 2.860